期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

去势抵抗性前列腺癌治疗药物开发

Development of therapeutic drug for castration-resistant prostate cancer
原文传递
导出
摘要 至今能延长前列腺癌患者生命的有效治疗手段尚少,去势抵抗性前列腺癌(CRPC)是前列腺癌治疗的难点和重点之一。延长转移性CRPC患者生存期的治疗药物开发是目前关注的热点。本文系统综述抗雄激素药物、细胞毒药物和免疫抑制剂等几大类药物用于CRPC治疗的临床评价。 The treatment of castrate refractory-resistant cancer （CRPC）is still a challenge, as there are few effective therapies to lengthen life of patients. Many novel approaches with extended survival benefit are currently in development yielded promising results for patients. This review describes the therapeutic drug for CRPC.
作者 周向军 张杰
机构地区 武汉大学人民医院泌尿外科 湖北理工学院附属黄石中心医院
出处 《世界临床药物》 CAS 2014年第2期74-79,共6页 World Clinical Drug
关键词 抗雄激素治疗 去势抵抗性前列腺癌(CRPC) 细胞毒药物治疗 免疫治疗 靶向治疗 antiandrogen thearpy castrate-resistant prostate cancer （CRPC） cytotoxic therapy immunotherapy targeted therapy
分类号 R737.25 [医药卫生—肿瘤] R979.19 [医药卫生—药品]
  • 相关文献

参考文献3

二级参考文献35

  • 1孙忠全,钱伟庆,宋建达.磷酸雌二醇氮芥联合足叶乙甙治疗激素抵抗性前列腺癌[J].中华泌尿外科杂志,2006,27(1):46-48. 被引量：5
  • 2US Food and Drug Administration. FDA approves Zytiga for late-stage prostate cancer [ EB/OL ]. [ 2011 - 04 - 28 ]. http ://www. fda. gov/NewsEvents/N nouncements/ucm253055, htm.
  • 3POTTER G A, BARRIE S E, JARMAN M, et al. Novel steroidal inhibitors of human cytochrome P45017a ( 17α-hydroxylase-CIT.20-1yase) :potential agents for the treatment of prostatic cancer[ J]. J Med Chem, 1995,38 ( 13 ) :2463 - 2471.
  • 4BURY P S. Process for the preparation of 17-0-vinyl-triflates as intermediates : WO,2006/021777A1 [ P]. 2006 - 03 - 02.
  • 5AGARWAJ N, HUTSON T E, VOGELZANG N J, et al. Abiraterone acetate:a promising drug for the treatment of castra- tion-resistant prostate cancer [ J ]. Future Oncol, 2010,6 ( 5 ) : 665 - 679.
  • 6Beltinger C, Fulda S, Kammertoens T, et al. Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases [J].Proc Natl Acad Sci USA, 1999, 96(15):8699-8704.
  • 7Martiniello-Wilks R, Garcia-Aragon J, Daja M M, et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors [J]. Hum Gene Ther,1998, 9(11):1617-
  • 8Lilia H, Haese A, Bjork T, et al. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy[J]. J Urol,1999, 1
  • 9Marcelli M, Cunningham G R, Walkup M,et al. Signaling pathway activated during apotosis of the prostate cancer cell line LNCaP:overexpression of caspase-7 as a new gene therapy strategy for prostate cancer[J]. Cancer Res, 1999, 59(2):382-390.
  • 10Geraghty P J, Chang A E. Basic principles associated with gene therapy of cancer [J].Surg Oncol, 1995, 4(3):125-137.

共引文献18

世界临床药物
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部